The Women's Health Initiative trial and related studies: 10 years later: a clinician's view - PubMed (original) (raw)
Review
The Women's Health Initiative trial and related studies: 10 years later: a clinician's view
Elizabeth P Gurney et al. J Steroid Biochem Mol Biol. 2014 Jul.
Abstract
The Women's Health Initiative (WHI) assessed the long-term effects of hormone therapy (HT) in postmenopausal women. The WHI started HT treatment on women aged 50-79 years in order to ascertain these effects. The study was ended early, due to findings of increased risk of coronary heart disease, breast cancer, stroke, and thromboembolic complications in women receiving estrogen plus progestin, compared to placebo. An increased risk of thromboembolic complications was also demonstrated in the estrogen only component of the WHI. The WHI results were initially reported for all subjects, and showed little difference when data were not analyzed by age. New WHI sub-analyses stratifying results by age, and an extended follow-up of the WHI offer a more complete picture of the effects of HT, revealing that starting HT in postmenopausal women less than ten years from last menstrual period appears to have less risk. In addition, hysterectomized women treated with estrogen only in the WHI have showed less risk of adverse outcomes than women in the estrogen plus progestin group. In this paper, we review data supporting the use of HT administered to postmenopausal women, showing it to have more benefit than risk for symptom control, prevention of bone mineral loss and fracture, and improvement of the metabolic profile in women who began HT when they were less than 60 years of age and had their last menstrual period less than ten years previous. In hysterectomized women treated with estrogen only, a reduction in breast cancer risk was noted in all age groups. The WHI raised many important questions. Ten years later, some have been answered, including confirmation that HT for most newly menopausal women is safe and effective. The treatment of the aging woman, including hormone treatment after menopause, should remain one of our highest research priorities. This article is part of a Special Issue entitled 'Menopause'.
Keywords: Hormone therapy; Menopause; Women's Health Initiative.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Similar articles
- Recent epidemiological evidence relevant to the clinical management of the menopause.
Shapiro S. Shapiro S. Climacteric. 2007 Oct;10 Suppl 2:2-15. doi: 10.1080/13697130701606754. Climacteric. 2007. PMID: 17882666 Review. - Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D; WHIMS Investigators. Rapp SR, et al. JAMA. 2003 May 28;289(20):2663-72. doi: 10.1001/jama.289.20.2663. JAMA. 2003. PMID: 12771113 Clinical Trial. - The WHI ten year's later: an epidemiologist's view.
Lacey JV Jr. Lacey JV Jr. J Steroid Biochem Mol Biol. 2014 Jul;142:12-5. doi: 10.1016/j.jsbmb.2013.08.006. Epub 2013 Sep 9. J Steroid Biochem Mol Biol. 2014. PMID: 24029430 Review. - Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
[No authors listed] [No authors listed] Prescrire Int. 2004 Jun;13(71):106-9. Prescrire Int. 2004. PMID: 15233153 - New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
Modena MG, Sismondi P, Mueck AO, Kuttenn F, Lignières Bd, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR; TREAT. Modena MG, et al. Maturitas. 2005 Sep 16;52(1):1-10. doi: 10.1016/j.maturitas.2005.05.003. Maturitas. 2005. PMID: 15963666 Review.
Cited by
- Estetrol/GPER/SERPINB2 transduction signaling inhibits the motility of triple-negative breast cancer cells.
Cirillo F, Spinelli A, Talia M, Scordamaglia D, Santolla MF, Grande F, Rizzuti B, Maggiolini M, Gérard C, Lappano R. Cirillo F, et al. J Transl Med. 2024 May 13;22(1):450. doi: 10.1186/s12967-024-05269-6. J Transl Med. 2024. PMID: 38741146 Free PMC article. - New Insights on the Progesterone (P4) and PGRMC1/NENF Complex Interactions in Colorectal Cancer Progression.
Kamińska J, Koper-Lenkiewicz OM, Ponikwicka-Tyszko D, Lebiedzińska W, Palak E, Sztachelska M, Bernaczyk P, Dorf J, Guzińska-Ustymowicz K, Zaręba K, Wołczyński S, Rahman NA, Dymicka-Piekarska V. Kamińska J, et al. Cancers (Basel). 2023 Oct 20;15(20):5074. doi: 10.3390/cancers15205074. Cancers (Basel). 2023. PMID: 37894441 Free PMC article. - The Comparative Study of the Administration of the Combination Preparation of Isoflavones and Hyaluronic Acid in Menopausal Women for the Treatment of the Symptoms of Menopause, Urogenital Atrophy and Oteoporosis in Relation to Existing Hormone Replacement Therapies.
Chalkidou A, Oikonomou E, Lambrinos D, Bothou A, Kyriakou D, Nikolettos K, Marinos G, Iatrakis G, Zervoudis S, Nikolettos N, Tsikouras P. Chalkidou A, et al. Mater Sociomed. 2023 Sep;35(3):206-214. doi: 10.5455/msm.2023.35.206-214. Mater Sociomed. 2023. PMID: 37795159 Free PMC article. - Role of estrogen in the regulation of central and peripheral energy homeostasis: from a menopausal perspective.
Zhu J, Zhou Y, Jin B, Shu J. Zhu J, et al. Ther Adv Endocrinol Metab. 2023 Sep 15;14:20420188231199359. doi: 10.1177/20420188231199359. eCollection 2023. Ther Adv Endocrinol Metab. 2023. PMID: 37719789 Free PMC article. Review. - The G protein-coupled oestrogen receptor GPER in health and disease: an update.
Prossnitz ER, Barton M. Prossnitz ER, et al. Nat Rev Endocrinol. 2023 Jul;19(7):407-424. doi: 10.1038/s41574-023-00822-7. Epub 2023 May 16. Nat Rev Endocrinol. 2023. PMID: 37193881 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical